Cargando…

Graves’ Thyrotoxicosis Following SARS-CoV-2 Infection

OBJECTIVE: Graves’ disease is an autoimmune thyroid disease that is thought to develop following environmental exposure in patients with genetic predisposition. Our objective is to present the first report of Graves’ disease onset immediately following recovery from mild coronavirus disease 2019 (CO...

Descripción completa

Detalles Bibliográficos
Autores principales: Harris, Asaf, Al Mushref, Mazen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association of Clinical Endocrinology 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834282/
https://www.ncbi.nlm.nih.gov/pubmed/33521256
http://dx.doi.org/10.1016/j.aace.2020.12.005
_version_ 1783642247904886784
author Harris, Asaf
Al Mushref, Mazen
author_facet Harris, Asaf
Al Mushref, Mazen
author_sort Harris, Asaf
collection PubMed
description OBJECTIVE: Graves’ disease is an autoimmune thyroid disease that is thought to develop following environmental exposure in patients with genetic predisposition. Our objective is to present the first report of Graves’ disease onset immediately following recovery from mild coronavirus disease 2019 (COVID-19), a close temporal occurrence that should be studied further. METHODS: We describe the clinical course and laboratory features, including thyroid function studies, antibody testing, and polymerase chain reaction testing for severe acute respiratory syndrome coronavirus 2. RESULTS: A 21-year-old woman with prediabetes, obesity, asthma, and gastroesophageal reflux disease presented to the emergency department reporting 3 days of tachycardia, palpitations, anxiety, and shortness of breath. Laboratory investigation revealed a thyroid-stimulating hormone level of 0.01 (0.30-5.00) mcIU/mL with a free thyroxine level of 3.8 (0.6-1.6) ng/dL, prompting endocrinology consultation. On physical examination, she had mild diffuse thyromegaly without tenderness and a history, which included hypothyroidism in her mother. Antibody testing results demonstrated thyroid-stimulating immunoglobulin and thyrotropin receptor antibody levels of 2.6 (<1.3) thyroid-stimulating immunoglobulin index and 17 (0.00-1.75) IU/L, respectively. Sixteen days before presenting to the ED, she was diagnosed with COVID-19 by polymerase chain reaction test after reporting typical symptoms, including fever. Infectious symptoms resolved within 10 days. She achieved clinical and laboratory improvements with a combination of methimazole and beta blocker therapy. CONCLUSION: This case documents the occurrence of Graves’ thyrotoxicosis following mild symptomatic COVID-19. Whether the preceding infection is coincidental or contributed to GD development requires definitive studies. This presentation may align with the theory of a viral link in the development of autoimmune thyroid disease in those with genetic predisposition.
format Online
Article
Text
id pubmed-7834282
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Association of Clinical Endocrinology
record_format MEDLINE/PubMed
spelling pubmed-78342822021-01-26 Graves’ Thyrotoxicosis Following SARS-CoV-2 Infection Harris, Asaf Al Mushref, Mazen AACE Clin Case Rep Case Report OBJECTIVE: Graves’ disease is an autoimmune thyroid disease that is thought to develop following environmental exposure in patients with genetic predisposition. Our objective is to present the first report of Graves’ disease onset immediately following recovery from mild coronavirus disease 2019 (COVID-19), a close temporal occurrence that should be studied further. METHODS: We describe the clinical course and laboratory features, including thyroid function studies, antibody testing, and polymerase chain reaction testing for severe acute respiratory syndrome coronavirus 2. RESULTS: A 21-year-old woman with prediabetes, obesity, asthma, and gastroesophageal reflux disease presented to the emergency department reporting 3 days of tachycardia, palpitations, anxiety, and shortness of breath. Laboratory investigation revealed a thyroid-stimulating hormone level of 0.01 (0.30-5.00) mcIU/mL with a free thyroxine level of 3.8 (0.6-1.6) ng/dL, prompting endocrinology consultation. On physical examination, she had mild diffuse thyromegaly without tenderness and a history, which included hypothyroidism in her mother. Antibody testing results demonstrated thyroid-stimulating immunoglobulin and thyrotropin receptor antibody levels of 2.6 (<1.3) thyroid-stimulating immunoglobulin index and 17 (0.00-1.75) IU/L, respectively. Sixteen days before presenting to the ED, she was diagnosed with COVID-19 by polymerase chain reaction test after reporting typical symptoms, including fever. Infectious symptoms resolved within 10 days. She achieved clinical and laboratory improvements with a combination of methimazole and beta blocker therapy. CONCLUSION: This case documents the occurrence of Graves’ thyrotoxicosis following mild symptomatic COVID-19. Whether the preceding infection is coincidental or contributed to GD development requires definitive studies. This presentation may align with the theory of a viral link in the development of autoimmune thyroid disease in those with genetic predisposition. American Association of Clinical Endocrinology 2020-12-28 /pmc/articles/PMC7834282/ /pubmed/33521256 http://dx.doi.org/10.1016/j.aace.2020.12.005 Text en © 2020 AACE. Published by Elsevier Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Harris, Asaf
Al Mushref, Mazen
Graves’ Thyrotoxicosis Following SARS-CoV-2 Infection
title Graves’ Thyrotoxicosis Following SARS-CoV-2 Infection
title_full Graves’ Thyrotoxicosis Following SARS-CoV-2 Infection
title_fullStr Graves’ Thyrotoxicosis Following SARS-CoV-2 Infection
title_full_unstemmed Graves’ Thyrotoxicosis Following SARS-CoV-2 Infection
title_short Graves’ Thyrotoxicosis Following SARS-CoV-2 Infection
title_sort graves’ thyrotoxicosis following sars-cov-2 infection
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834282/
https://www.ncbi.nlm.nih.gov/pubmed/33521256
http://dx.doi.org/10.1016/j.aace.2020.12.005
work_keys_str_mv AT harrisasaf gravesthyrotoxicosisfollowingsarscov2infection
AT almushrefmazen gravesthyrotoxicosisfollowingsarscov2infection